Immunic, Inc. appointed Jon Congleton to its Board of Directors, effective March 27, 2026. Mr. Congleton will serve as a Class II director until the 2028 annual meeting of stockholders and will chair the Compensation Committee. The Board size increased from eight to nine directors in connection with this appointment. Mr. Congleton brings nearly 40 years of biopharmaceutical experience, including leadership roles at Mineralys Therapeutics, Impel NeuroPharma, Nivalis Therapeutics, and over 18 years at Teva Pharmaceutical Industries Ltd. He played a key role in the U.S. launch of Teva's Copaxone, a leading multiple sclerosis treatment. As part of his compensation, Mr. Congleton received an inaugural grant of options to purchase 500,000 shares of common stock, vesting monthly over three years, with an exercise price equal to the closing price on March 27, 2026, subject to shareholder approval. He will also receive cash compensation in accordance with the company's non-employee director compensation policy.